Sankt Gorans Sjukhus

At Sankt Gorans Sjukhus, oncology trials are strongly centered on breast cancer, including early, non-metastatic, and advanced disease. The studies explore new treatment combinations and personalized approaches aimed at improving response, reducing recurrence, and supporting longer-term outcomes.

• Neoadjuvant and adjuvant strategies for early breast cancer and triple-negative breast cancer
• Targeted and biomarker-informed approaches for HER2-positive and ER-positive disease
• Research designed to improve treatment effectiveness and reduce the risk of cancer returning

This work includes efforts to refine personalized oncology and identify better treatment options for patients with high-risk or treatment-resistant disease.

The site also supports clinical research in prostate cancer and related genitourinary conditions, with a focus on improving disease control and delaying progression in higher-risk patients. These trials examine whether newer treatment combinations can strengthen standard care.

• Studies in high-risk prostate cancer and recurrent disease
• Trials using biomarker-driven strategies to guide treatment choice
• Research aimed at improving progression-free and metastasis-free outcomes

The research portfolio reflects a broader interest in male urogenital diseases and more tailored treatment planning.

Clinical research at this hospital includes several studies in cardiovascular diseases, especially heart failure, thrombotic complications, and outcomes after acute cardiac events. The trials are designed to test whether newer therapies can reduce hospitalizations, improve recovery, and lower the risk of cardiovascular death.

• Studies in heart failure with preserved ejection fraction and related metabolic conditions
• Research on left ventricular thrombosis after acute myocardial infarction
• Trials evaluating better strategies for preventing complications and improving patient outcomes

This area highlights an ongoing effort to improve care for patients with complex cardiac disease and overlapping comorbidities.

The oncology program includes studies in colorectal cancer and other solid tumors, focusing on whether new treatment approaches can improve disease control after surgery or in advanced disease. These trials aim to strengthen treatment effectiveness and extend the time before recurrence or progression.

• Research in metastatic colorectal cancer and stage II-III disease
• Trials targeting tumors with specific molecular alterations
• Studies assessing whether treatment can better prevent recurrence and improve survival

The work contributes to broader neoplasm research by matching treatment strategies more closely to tumor biology.

Sankt Gorans Sjukhus also participates in trials outside oncology, including nervous system diseases and infectious conditions. These studies are designed to improve recovery after acute neurological events and to evaluate treatments that may limit injury or relieve symptoms.

• Research in acute ischemic stroke aimed at improving functional recovery
• Studies of vestibular neuritis to reduce dizziness and related symptoms
• Infection-focused trials in tick-borne encephalitis and antibiotic-resistant urinary infections

Together, these projects show a broader interest in both neurology and virus diseases, as well as practical improvements in infection management.

The site’s research portfolio includes studies in hematologic diseases, particularly lymphomas and acute leukemia, with some trials also touching on broader cancer biology. These projects are focused on improving treatment response and identifying more effective options for patients with aggressive or difficult-to-treat disease.

• Trials in follicular lymphoma and other lymphoid cancers
• Research in acute leukemia and related blood cancers
• Studies aimed at testing new therapies and refining treatment selection

This area adds depth to the hospital’s oncology program by extending research into both solid and blood cancers.